Penetrium Bioscience touts ‘false resistance’ theory, but faces hurdles including human validation

Penetrium Bioscience, which has declared a shift from a contract research organization (CRO) to a biotech venture, is engaging with the market around Penetrium, an anticancer candidate repurposed from an anthelmintic ingredient. But the company still faces substantial hurdles, including validation in humans.

The company disclosed last September that the U.S. Food and Drug Administration (FDA) had cleared its investigational plan for a phase 2a trial in advanced solid tumors. It later held a global clinical development symposium in Seoul, where it presented preclinical data to clinicians from South Korea and abroad.

The company’s central theory is that cancer-associated fibroblasts, tumor-associated macrophages and the extracellular matrix form a dense mesh that blocks anticancer drugs from reaching cancer cells. It calls the phenomenon “false resistance”: drugs retain activity against the cancer cells themselves, but a barrier around them prevents the drugs from working.

Under the company’s approach, Penetrium would break down the stromal barrier and be administered in combination with existing targeted anticancer drugs, chemotherapy or immune checkpoint inhibitors to restore drug delivery.

The symposium focused in part on experiments involving patient-derived lung and ovarian cancer organoids co-cultured with cancer-associated fibroblasts. The company presented data showing that combining the targeted anticancer drug daraxonrasib with Penetrium sharply reduced cancer cell viability within the stromal barrier.

The company reported a 96% inhibition rate for lung metastasis when Penetrium was combined with an immunotherapy drug in animal experiments, and a 92% inhibition rate for tumor growth when it was combined with the pancreatic cancer drug gemcitabine. The company said Marina Chiara Garassino, a professor at the University of Chicago, and Brian Henick, a professor at Columbia University, had agreed to participate as investigators in the U.S. trial.

Industry and clinical experts, however, point to a fundamental limitation: The figures cited by the company have not yet been directly confirmed through administration to humans. They say it remains unclear whether effects seen in preclinical cell and rodent models will be reproduced in the complex tumor microenvironment in humans.

Attempts to target the tumor microenvironment and ease the extracellular matrix have been pursued repeatedly by global pharmaceutical companies, with most failing to deliver results. Concerns also remain that weakening the stromal barrier could instead promote cancer cells’ entry into blood vessels and distant metastasis, or cause systemic toxicity.

The design of the newly cleared U.S. phase 2a trial is also considered far from rigorous proof of efficacy. The disclosure lists just 18 participants across three U.S. sites. It is an exploratory basket trial that does not specify a particular cancer type and combines the drug with standard treatment in patients with various advanced solid tumors.

Because it is a small exploratory trial without hypothesis testing to assess statistical significance, it will be difficult to draw firm conclusions about the drug’s efficacy from this study. The estimated trial completion date is September 2028, meaning it will take at least two more years for human response rates and the safety profile to begin to take shape.

Structural limitations surrounding the pipeline’s underlying rights have also been raised. Penetrium’s main ingredient is niclosamide, which has been used as an anthelmintic. The company says it improved the drug’s limitations—poor water solubility and low bioavailability—by incorporating drug-delivery technology from its parent company, Hyundai Bioscience, and C&Pharm.

However, the exclusive license for solid tumors that the company secured from C&Pharm explicitly excludes prostate and pancreatic cancers, which have significant market potential. This creates a contradiction: The company has used combination data in pancreatic cancer and the mechanism in prostate cancer as key promotional points in symposium and presentation materials, even though the commercial benefits of those areas remain outside the license.

Market doubts also persist about a governance imbalance in which Penetrium Bioscience, a KOSDAQ-listed company, bears the R&D risk while rights to valuable indications belong to its parent company and affiliates.

Financial fundamentals are another risk. The contract research services that the company had focused on since its days as ADM Korea have become less profitable amid intensifying competition for contracts and a downturn in biotech investment. In 2025, the company reported revenue of 9.2 billion won, an operating loss of 7.3 billion won and a net loss of 14.8 billion won, marking its third consecutive year in the red.

The company’s own operating activities are not enough to cover the clinical costs required for drug development. It carried out a 73.9 billion won rights offering last May. Although it said it would invest more than 55 billion won in developing its drug pipeline, R&D spending is bound to accelerate as trials advance.

Market participants who remember the parent company’s past efforts to develop niclosamide-based COVID-19 treatments and other drugs say the current situation feels familiar. There have been numerous precedents in which splashy preclinical efficacy announcements, publicity about the participation of overseas researchers and news of contact with global regulators did not lead to commercialization.

Penetrium Bioscience’s proposed approach to overcoming “false resistance” may be an intriguing topic in oncology, but for now it remains at the starting point: exploring an early-stage hypothesis in a small patient group. The involvement of prominent overseas scholars and preclinical results do not guarantee a drug’s ultimate success.

The market is watching closely to see whether the company can statistically demonstrate meaningful safety and tumor response signals in a small basket trial, and whether it can create independent commercial value within the limited scope of its license and overcome its chronic losses.